https://scholars.lib.ntu.edu.tw/handle/123456789/637991
標題: | Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial | 作者: | Zeidan, Amer M Ando, Kiyoshi Rauzy, Odile Turgut, Mehmet Wang, Ming-Chung Cairoli, Roberto HSIN-AN HOU Kwong, Yok-Lam Arnan, Montserrat Meers, Stef Pullarkat, Vinod Santini, Valeria Malek, Kamel Kiertsman, Flavia Niolat, Julie Ramos, Pedro Marques Menssen, Hans D Fenaux, Pierre Miyazaki, Yasushi Platzbecker, Uwe |
公開日期: | 5-十二月-2023 | 來源出版物: | The Lancet. Haematology | 摘要: | Sabatolimab is an immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), an immuno-myeloid regulator expressed on immune cells and leukaemic stem cells. In this trial, we compared the efficacy and safety of sabatolimab plus hypomethylating agent with placebo plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes. |
URI: | https://pubmed.ncbi.nlm.nih.gov/38065203/ https://scholars.lib.ntu.edu.tw/handle/123456789/637991 |
ISSN: | 23523026 | DOI: | 10.1016/S2352-3026(23)00333-2 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。